Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

23.50 +0.30 (+1.31%)
Streaming Delayed Price Updated: 10:04 AM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Via ACCESSWIRE
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
Eli Lilly and Company (LLY​​​​​​​) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. 
Via Talk Markets
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Via ACCESSWIRE
Promising Small Biotech Amphastar Sees Actionable Pullback
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views. 
Via MarketBeat
Amphastar Pharma: Q1 Earnings Insights
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Via ACCESSWIRE
Earnings Outlook For Amphastar Pharma
Via Benzinga
Abcam Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Records 52-Week High Tuesday Morning
Via Investor Brand Network
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
Via ACCESSWIRE
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday. 
Via Investor's Business Daily
Lilly to Divest BAQSIMI to Amphastar
Via ACCESSWIRE
Why Shares of Amphastar Pharmaceuticals Rose Today
The company reported a record revenue year and increased EPS. 
Via The Motley Fool
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash
Via Benzinga
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
Via ACCESSWIRE
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier. 
Via Investor's Business Daily
Alkermes Stock Sees Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Exelixis Stock Generating Improved Relative Strength Rating
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily
Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade
Vertex Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 67 to 77. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
Via ACCESSWIRE
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.